Professor Andersen obtained his medical degree from Copenhagen University and specialised in neurology. In the same year he also completed his doctoral thesis on SOD1 genetics and pathology in ALS. After this, he moved for one year to MGH/Harvard Medical School for his postdoctoral research. In 1992, he established the multidisciplinary Clinical Care ALS Team at Umeå University Hospital that cares for patients from northern Sweden and also sees second-opnion patients from other parts of Sweden and abroad. His research focuses on genetics, free radicals and SOD1 protein-prion research. He also has an interest in biomarker research. He has been a senior neurologist since 2001 and was appointed as a Professor in Neurology in 2010. He has won various prizes including the Charcot Prize (2000) and the Wallenberg Clinical Scholar 2016—2020 for focused ALS Research.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.